TCR2 THERAPEUTICS INC. Annual Operating Income (Loss) in USD from 2018 to 2022

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Tcr2 Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2018 to 2022.
  • Tcr2 Therapeutics Inc. Operating Income (Loss) for the quarter ending March 31, 2023 was -$41.5M, a 42.1% decline year-over-year.
  • Tcr2 Therapeutics Inc. Operating Income (Loss) for the twelve months ending March 31, 2023 was -$166M, a 54.4% decline year-over-year.
  • Tcr2 Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$153M, a 53.9% decline from 2021.
  • Tcr2 Therapeutics Inc. annual Operating Income (Loss) for 2021 was -$99.7M, a 45.2% decline from 2020.
  • Tcr2 Therapeutics Inc. annual Operating Income (Loss) for 2020 was -$68.7M, a 33.7% decline from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$153M -$53.8M -53.9% Jan 1, 2022 Dec 31, 2022 10-K 2023-03-23
2021 -$99.7M -$31M -45.2% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-23
2020 -$68.7M -$17.3M -33.7% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-22
2019 -$51.4M -$24.9M -94.2% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-16
2018 -$26.5M Jan 1, 2018 Dec 31, 2018 10-K 2020-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.